SK282524B6 - Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu - Google Patents

Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu Download PDF

Info

Publication number
SK282524B6
SK282524B6 SK101-95A SK10195A SK282524B6 SK 282524 B6 SK282524 B6 SK 282524B6 SK 10195 A SK10195 A SK 10195A SK 282524 B6 SK282524 B6 SK 282524B6
Authority
SK
Slovakia
Prior art keywords
methoxy
preparation
optically pure
methyl
pyridyl
Prior art date
Application number
SK101-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK10195A3 (en
Inventor
Per Lennart Lindberg
Unge Sverker Von
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK282524(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SK10195A3 publication Critical patent/SK10195A3/sk
Publication of SK282524B6 publication Critical patent/SK282524B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Medicinal Preparation (AREA)
SK101-95A 1993-05-28 1994-05-27 Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu SK282524B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds
PCT/SE1994/000509 WO1994027988A1 (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds

Publications (2)

Publication Number Publication Date
SK10195A3 SK10195A3 (en) 1995-09-13
SK282524B6 true SK282524B6 (sk) 2002-10-08

Family

ID=20390088

Family Applications (1)

Application Number Title Priority Date Filing Date
SK101-95A SK282524B6 (sk) 1993-05-28 1994-05-27 Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu

Country Status (43)

Country Link
US (5) US5693818A (ru)
EP (3) EP1020461B2 (ru)
JP (3) JP3549111B2 (ru)
KR (1) KR100337274B1 (ru)
CN (2) CN1055469C (ru)
AT (1) ATE197452T1 (ru)
CA (2) CA2337581A1 (ru)
CL (1) CL2009000805A1 (ru)
CY (1) CY2224B1 (ru)
CZ (1) CZ287876B6 (ru)
DE (4) DE69435220D1 (ru)
DK (3) DK1020461T4 (ru)
DZ (1) DZ1785A1 (ru)
EE (1) EE03157B1 (ru)
ES (3) ES2326405T5 (ru)
FI (2) FI117755B (ru)
GR (2) GR970300012T1 (ru)
HK (3) HK1008330A1 (ru)
HR (1) HRP940307B1 (ru)
HU (1) HU226824B1 (ru)
IL (1) IL109684A (ru)
IS (1) IS1854B (ru)
LT (1) LT3287B (ru)
LU (1) LU91870I2 (ru)
LV (1) LV11034B (ru)
MA (1) MA23210A1 (ru)
MY (1) MY121192A (ru)
NO (2) NO307378B1 (ru)
NZ (1) NZ266915A (ru)
PL (1) PL178994B1 (ru)
PT (3) PT652872E (ru)
RU (1) RU2137766C1 (ru)
SA (2) SA94140756B1 (ru)
SE (1) SE9301830D0 (ru)
SG (1) SG49283A1 (ru)
SI (2) SI22752B (ru)
SK (1) SK282524B6 (ru)
TN (1) TNSN94058A1 (ru)
TW (1) TW389761B (ru)
UA (1) UA60289C2 (ru)
WO (1) WO1994027988A1 (ru)
YU (1) YU49065B (ru)
ZA (1) ZA943557B (ru)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
EP1078628B1 (en) * 1994-07-08 2008-11-19 AstraZeneca AB Multiple unit tableted dosage form
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6328993B1 (en) * 1997-12-08 2001-12-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for an acid liable active proton pump inhibitor
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
ATE526022T1 (de) * 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd Stabilisierte zusammenstellungen die benzimidazole enthalten
KR100472126B1 (ko) 1998-08-10 2005-03-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 양성자 펌프 억제제의 프로드러그
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
KR100619200B1 (ko) 1998-11-18 2006-09-05 아스트라제네카 아베 개선된 화학적 제조 방법 및 제약 제형
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
JP2003501488A (ja) * 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
WO2001024780A2 (en) * 1999-10-01 2001-04-12 Natco Pharma Limited Soft gel capsule resistant to gastric juices
CN1197574C (zh) * 1999-10-20 2005-04-20 卫材株式会社 稳定苯并咪唑化合物的方法
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
DE60015607T2 (de) 2000-02-24 2005-11-10 Kopran Research Laboratories Ltd. Oral verabreichbare säurebeständige geschwürbehandelnde benzimidazolderivate
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
AU5248601A (en) * 2000-05-15 2001-11-26 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
AU2003204233B8 (en) * 2000-08-04 2008-06-26 Bernard Charles Sherman Magnesium salt of S-omeprazole
CA2417311C (en) 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
AU2002249935A1 (en) * 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
WO2002083608A2 (en) * 2001-04-13 2002-10-24 Apsinterm Llc Methods of preparing sulfinamide and sulfoxides
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CN1243749C (zh) 2001-09-18 2006-03-01 泽里新药工业株式会社 苯并咪唑衍生物
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
DK1487818T3 (da) * 2002-03-05 2007-08-20 Astrazeneca Ab Alkylammoniumsalte af omeprazol og esomeprazol
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
DK1556371T3 (da) * 2002-07-19 2006-08-21 Winston Pharmaceuticals Llc Benzimidazol-derivater og deres anvendelse som prodrugs for protonpumpe-inhibitorer
TW200410955A (en) * 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
JP4634144B2 (ja) * 2002-08-01 2011-02-16 ニコックス エスエー ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
CA2501424A1 (en) 2002-08-30 2004-03-11 Dr. Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
WO2004037253A1 (en) * 2002-10-22 2004-05-06 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
JP2006514985A (ja) 2002-12-06 2006-05-18 アルタナ ファルマ アクチエンゲゼルシャフト (s)−パントプラゾールの製造方法
AU2003289948B2 (en) 2002-12-06 2009-12-24 Takeda Gmbh Process for preparing optically pure active compounds
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CN1777598A (zh) * 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 S-奥美拉唑的多晶型物
AU2003238671A1 (en) * 2003-04-10 2004-11-01 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
WO2004099182A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
PL379542A1 (pl) * 2003-07-15 2006-10-02 Allergan, Inc. Sposób wytwarzania izomerycznie czystych proleków inhibitorów pompy protonowej
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005007117A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
PT1651217E (pt) * 2003-07-23 2008-05-23 Nycomed Gmbh Sais alcalinos de inibidores da bomba de protões
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
SE0302381D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
WO2005027880A1 (en) * 2003-09-25 2005-03-31 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
EP2184058B1 (en) 2003-09-26 2012-02-08 ALZA Corporation Drug coating providing high drug loading and methods for providing the same
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
AU2003272086A1 (en) * 2003-10-14 2005-04-27 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
BRPI0507784A (pt) * 2004-02-18 2007-07-17 Allergan Inc métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
CA2557471A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
ES2327926T3 (es) 2004-04-28 2009-11-05 Hetero Drugs Limited Procedimiento de preparacion de compuestos de piridinilmetil-1h-benzimidazol en forma de enantiomeros simples o enantiomericamente enriquecidos.
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1748998B1 (en) * 2004-05-28 2010-01-27 Hetero Drugs Limited A novel stereoselective synthesis of benzimidazole sulfoxides
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
EP1765806A1 (en) * 2004-06-24 2007-03-28 AstraZeneca AB New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
US20080249134A1 (en) * 2004-06-24 2008-10-09 Ursula Hohlneicher New Esomeprazole Sodium Salt Crystal Modification
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
CA2575718C (en) 2004-08-06 2010-12-14 Eisai R & D Management Co., Ltd. Salts of benzimidazole derivative with amines and process for manufacturing the same
KR100847635B1 (ko) * 2004-08-06 2008-07-21 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 유도체와 아민과의 염
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
JP4837722B2 (ja) 2005-03-25 2011-12-14 リブゾン ファーマシューティカル グループ インク. 置換スルホキシド化合物、その調製方法、およびその使用方法
EP1885711A1 (en) 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
US8841333B2 (en) * 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
EP1891043A1 (en) * 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
KR100641534B1 (ko) * 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
EP1940397A4 (en) * 2005-08-03 2010-01-20 Takeda Pharmaceuticals North A METHOD FOR TREATING HYPERTONIA
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7576219B2 (en) * 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
CA2631919A1 (en) 2005-12-05 2007-06-14 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
AU2006331373B2 (en) * 2005-12-28 2011-06-02 Union Quimico Farmaceutica, S.A. A process for the preparation of the (S)-enantiomer of omeprazole
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US20090197919A1 (en) * 2006-06-07 2009-08-06 Rolf Bergman Novel Method for Preparation of Ammonium Salts of Esomeprazole
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
JP2009542624A (ja) 2006-07-05 2009-12-03 ルピン・リミテッド スルホキシド化合物の光学的に純粋な又は光学的に富化されたエナンチオマーの調製方法
CA2658804A1 (en) 2006-07-25 2008-01-31 Vecta Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
KR20090103879A (ko) * 2006-11-13 2009-10-01 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
CN101646440A (zh) * 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
EA200900985A1 (ru) * 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения оптически чистого омепразола
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US8394963B2 (en) 2007-02-21 2013-03-12 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
US8492551B2 (en) * 2007-06-07 2013-07-23 Aurobindo Pharma. Ltd. Process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
ES2375515T3 (es) 2007-09-25 2012-03-01 Hetero Drugs Limited Procedimiento de preparación de esomeprazol enantiomericamente puro.
EP2195309A4 (en) * 2007-10-08 2013-04-24 Hetero Drugs Ltd SALT POLYMORPHS OF THE ESOMEPRAZOLE
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
WO2009105568A1 (en) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) * 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
EP2346854A4 (en) 2008-11-18 2012-10-17 Hetero Research Foundation OPTICAL PURIFICATION OF ESOMEPRAZOLE
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
JP2012531430A (ja) * 2009-06-25 2012-12-10 ポーゼン インコーポレイテッド アスピリン療法を必要とする患者を治療するための方法
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2534144B1 (en) 2010-02-12 2014-09-03 Esteve Química, S.A. Preparation process of the sodium salt of Esomeprazole
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
CN102816149B (zh) * 2011-06-10 2015-05-13 上海汇伦生命科技有限公司 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
CN102807561A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 S-奥美拉唑铝盐及其制备方法和应用
CN102850323A (zh) * 2011-06-30 2013-01-02 秦引林 一种埃索美拉唑钠的精制方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
AU2012351342A1 (en) 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
CN103420978A (zh) * 2012-05-15 2013-12-04 上海医药工业研究院 一种苯并咪唑类化合物的镁盐的制备方法
CN102657622A (zh) * 2012-05-17 2012-09-12 康普药业股份有限公司 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
CN102964335B (zh) * 2012-11-13 2014-06-25 凌元敏 一种埃索美拉唑钠化合物及其制备方法和用途
CN103159737B (zh) * 2013-04-12 2014-03-19 四川省惠达药业有限公司 一种埃索美拉唑钠化合物及药物组合物
US20160256399A1 (en) 2013-11-04 2016-09-08 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
CN107428726B (zh) 2014-12-26 2021-03-16 国立大学法人东京大学 光学活性的质子泵抑制剂化合物的制备方法
EP3064495B1 (en) 2015-03-06 2016-12-14 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of optically pure esomeprazole
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN105924430A (zh) * 2016-06-27 2016-09-07 杭州富阳伟文环保科技有限公司 一种埃索美拉唑钠的精制方法
WO2018191210A1 (en) * 2017-04-11 2018-10-18 Mclaughlin Gormley King Company Sabadilla oil and uses thereof
CN108409714A (zh) * 2018-03-29 2018-08-17 成都通德药业有限公司 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
WO2021011645A1 (en) * 2019-07-16 2021-01-21 Kindred Biosciences, Inc. Equine esomeprazole formulations and methods of use
JP7335002B2 (ja) 2019-08-29 2023-08-29 学校法人東京理科大学 スルホキシド化合物のエナンチオマー調製方法及びエナンチオマー調製システム
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4636085A (en) * 1982-03-16 1987-01-13 Mapro Inc. Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US4445708A (en) * 1983-05-09 1984-05-01 General Motors Corporation Energy absorbing steering column for vehicles
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
EP0695123A4 (en) * 1993-04-27 1996-09-11 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING GASTRICAL FAULTS USING OPTICALLY PURE PANTOPRAZOLS
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
EP1078628B1 (en) * 1994-07-08 2008-11-19 AstraZeneca AB Multiple unit tableted dosage form
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound

Also Published As

Publication number Publication date
PT1020460E (pt) 2009-07-29
AU6902494A (en) 1994-12-20
SK10195A3 (en) 1995-09-13
SE9301830D0 (sv) 1993-05-28
EP1020460B1 (en) 2009-07-22
IL109684A0 (en) 1994-12-29
JPH07509499A (ja) 1995-10-19
HU226824B1 (en) 2009-11-30
EP1020460A3 (en) 2003-10-15
JP2004043493A (ja) 2004-02-12
ES2326405T5 (es) 2016-02-15
IS1854B (is) 2003-02-21
CN1110477A (zh) 1995-10-18
HK1008330A1 (en) 1999-05-07
FI117755B (fi) 2007-02-15
ES2326404T3 (es) 2009-10-09
PL178994B1 (pl) 2000-07-31
JP4039999B2 (ja) 2008-01-30
HK1028044A1 (en) 2001-02-02
EP1020461A3 (en) 2006-10-04
UA60289C2 (ru) 2003-10-15
ES2326405T3 (es) 2009-10-09
EP1020461B2 (en) 2015-10-21
PL307261A1 (en) 1995-05-15
DK1020461T3 (da) 2009-08-10
HRP940307B1 (en) 2001-06-30
SA05260103B1 (ar) 2010-01-31
US20080312449A1 (en) 2008-12-18
EP1020461B1 (en) 2009-07-22
FI20070002A (fi) 2007-01-02
HUT71888A (en) 1996-02-28
CA2139653A1 (en) 1994-12-08
SI22752B (sl) 2010-01-29
FI950377A (fi) 1995-01-27
NO2011009I1 (no) 2011-06-20
JP3549111B2 (ja) 2004-08-04
CN1259346A (zh) 2000-07-12
ES2099047T1 (es) 1997-05-16
RU95105587A (ru) 1996-10-27
SI9420002A (en) 1995-08-31
ATE197452T1 (de) 2000-11-11
JP2004043494A (ja) 2004-02-12
NO950263L (no) 1995-01-24
SI22752A (sl) 2009-10-31
LV11034B (en) 1996-10-20
LT3287B (en) 1995-06-26
DE69435221D1 (de) 2009-09-03
PT652872E (pt) 2001-04-30
SA94140756B1 (ar) 2006-05-20
MA23210A1 (fr) 1994-12-31
YU31494A (sh) 1997-05-28
WO1994027988A1 (en) 1994-12-08
YU49065B (sh) 2003-08-29
US5693818A (en) 1997-12-02
DZ1785A1 (fr) 2002-02-17
CA2337581A1 (en) 1994-12-08
CY2224B1 (en) 2003-04-18
US6143771A (en) 2000-11-07
KR950702553A (ko) 1995-07-29
FI950377A0 (fi) 1995-01-27
CA2139653C (en) 2001-07-10
IS4161A (is) 1994-11-29
NO307378B1 (no) 2000-03-27
DE69426254T2 (de) 2001-06-07
NO950263D0 (no) 1995-01-24
TW389761B (en) 2000-05-11
CZ20295A3 (en) 1995-10-18
TNSN94058A1 (fr) 1995-04-25
CN1107503C (zh) 2003-05-07
SG49283A1 (en) 1998-05-18
KR100337274B1 (ko) 2003-12-31
DK1020460T3 (da) 2009-08-10
JP3959056B2 (ja) 2007-08-15
EE03157B1 (et) 1999-02-15
AU676337B2 (en) 1997-03-06
DE69426254D1 (de) 2000-12-14
ES2099047T3 (es) 2001-03-01
HK1028045A1 (en) 2001-02-02
HU9500247D0 (en) 1995-03-28
LU91870I2 (fr) 2011-11-21
DE652872T1 (de) 1997-09-04
MY121192A (en) 2006-01-28
ZA943557B (en) 1995-04-11
EP0652872A1 (en) 1995-05-17
GR970300012T1 (en) 1997-05-31
EP0652872B1 (en) 2000-11-08
IL109684A (en) 2002-05-23
NZ266915A (en) 1996-10-28
US20100222591A1 (en) 2010-09-02
PT1020461E (pt) 2009-07-29
EP1020460A2 (en) 2000-07-19
CL2009000805A1 (es) 2009-08-21
EP1020461A2 (en) 2000-07-19
DE69435220D1 (de) 2009-09-03
DK1020461T4 (en) 2016-02-15
LV11034A (lv) 1996-02-20
GR3035365T3 (en) 2001-05-31
US5714504A (en) 1998-02-03
LTIP1941A (en) 1994-12-27
CZ287876B6 (cs) 2001-03-14
HRP940307A2 (en) 1996-12-31
CN1055469C (zh) 2000-08-16
RU2137766C1 (ru) 1999-09-20
SI9420002B (sl) 2009-12-31
DK0652872T3 (da) 2001-03-05

Similar Documents

Publication Publication Date Title
SK282524B6 (sk) Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu
US6875872B1 (en) Compounds
EP0712401A1 (en) Novel dialkoxy-pyridinyl-benzimidazole derivatives
AU676337C (en) Optically pure salts of pyridinylmethyl sulfinyl-IH- benzimidazole compounds
EP0712400A1 (en) Novel substituted benzimidazoles
HUT61995A (en) Process for producing fluorine-substituted benzimidazole derivatives and pharmaceutical compositions comprising same
SK5896A3 (en) Substituted benzimideazoles

Legal Events

Date Code Title Description
SPCF Filing of an spc

Free format text: PRODUCT NAME: NAPROXEN A EZOMEPRAZOL; NAT. REGISTRATION NO/DATE: 29/0782/10-S 20101112; FIRST REGISTRATION: GB PL 17901/0263 - 0001 20101105

Spc suppl protection certif: 4-2011

Filing date: 20110510

SPCR Rejection of an spc

Free format text: PRODUCT NAME: NAPROXEN A EZOMEPRAZOL; NAT. REGISTRATION NO/DATE: 29/0782/10-S 20101112; FIRST REGISTRATION; GB PL 17901/0263 20101105

Spc suppl protection certif: 4-2011

Filing date: 20110510

MG4A Partial revocation of patent

Effective date: 20121212

MK4A Patent expired

Expiry date: 20140527